• +1-646-491-9876
    • +91-20-67278686

    Search

    Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H1 2017

    Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H1 2017

    • Report Code ID: RW0001709459
    • Category Pharmaceuticals
    • No. of Pages 173
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H1 2017, provides an overview of the Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline landscape.

    H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called avian influenza. This virus can spread to humans. Symptoms include fever and cough, acute respiratory distress, shortness of breath/difficulty breathing, abdominal pain and diarrhea. Predisposing factors include work with poultry, touch an infected bird and eating raw or undercooked poultry meat. Treatment includes antiviral medications.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H5N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 5, 14, 1, 30 and 7 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively.

    Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 5
    List of Figures 6
    Introduction 7
    Publisher Report Coverage 7
    Influenza A Virus, H5N1 Subtype Infections - Overview 8
    Influenza A Virus, H5N1 Subtype Infections - Therapeutics Development 9
    Pipeline Overview 9
    Pipeline by Companies 10
    Pipeline by Universities/Institutes 14
    Products under Development by Companies 15
    Products under Development by Universities/Institutes 19
    Influenza A Virus, H5N1 Subtype Infections - Therapeutics Assessment 20
    Assessment by Target 20
    Assessment by Mechanism of Action 22
    Assessment by Route of Administration 24
    Assessment by Molecule Type 26
    Influenza A Virus, H5N1 Subtype Infections - Companies Involved in Therapeutics Development 28
    Akshaya Bio Inc 28
    Altimmune Inc 28
    Antigen Express Inc 29
    Aphios Corp 29
    BioDiem Ltd 30
    BiondVax Pharmaceuticals Ltd 30
    CEL-SCI Corp 31
    Cocrystal Pharma Inc 31
    Curevac AG 32
    Fab'entech SA 32
    Gemmus Pharma Inc 33
    GlaxoSmithKline Plc 33
    Hemispherx Biopharma Inc 34
    iBio Inc 34
    Inovio Pharmaceuticals Inc 35
    Johnson & Johnson 35
    Kineta Inc 36
    Lakewood-Amedex Inc 36
    Medicago Inc 37
    Medigen Vaccine Biologics Corp 37
    Microbiotix Inc 38
    NanoBio Corp 38
    Nanotherapeutics Inc 39
    NanoViricides Inc 39
    NewLink Genetics Corp 40
    OPKO Health Inc 40
    PaxVax Inc 41
    PeptiDream Inc 41
    Shionogi & Co Ltd 42
    Takeda Pharmaceutical Company Ltd 43
    TechnoVax Inc 43
    TGV-Inhalonix Inc 44
    Vaxart Inc 44
    Vaxine Pty Ltd 45
    VaxInnate Corp 45
    Visterra Inc 46
    Influenza A Virus, H5N1 Subtype Infections - Drug Profiles 47
    AE-AI vaccine - Drug Profile 47
    Alferon LDO - Drug Profile 48
    APP-0205 - Drug Profile 50
    APP-309 - Drug Profile 51
    AT-301 - Drug Profile 52
    CC-42344 - Drug Profile 53
    CEL-1000 - Drug Profile 54
    CHOS-05 - Drug Profile 56
    DPC-005 - Drug Profile 57
    FBF-001 - Drug Profile 58
    Gamma-Flu - Drug Profile 59
    GP-1001 - Drug Profile 60
    GP-1002 - Drug Profile 61
    GP-1681 - Drug Profile 62
    GREFLU/VIE - Drug Profile 64
    HAI-05 - Drug Profile 65
    HB-36.6 - Drug Profile 67
    Influ-nRNA - Drug Profile 68
    influenza [strain A/H5N1] (split virion) vaccine - Drug Profile 69
    influenza [strain A/H5N1] (virus like particle) vaccine 2 - Drug Profile 70
    influenza [strain A/H5N1] vaccine - Drug Profile 73
    influenza [strain A/H5N1] vaccine - Drug Profile 74
    influenza [strain A/H5N1] vaccine - Drug Profile 75
    influenza [strain A/H5N1] vaccine - Drug Profile 77
    influenza [strain A/H5N1] vaccine - Drug Profile 78
    influenza [strain A/H5N1] vaccine - Drug Profile 79
    influenza [strain A/H5N1] vaccine - Drug Profile 80
    influenza [strain A/H5N1] vaccine - Drug Profile 81
    influenza [strain A/H5N1] vaccine - Drug Profile 82
    influenza [strain A/H5N1] vaccine 2 - Drug Profile 83
    influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile 84
    influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile 85
    influenza [strains A/H1N1 + A/H5N1] vaccine - Drug Profile 86
    influenza [strains A/H5N1 + A/H1N1] vaccine - Drug Profile 87
    influenza [strains A/H5N1 + A/H7N2 + A/H9N2 + A/H7N3 + A/ H5N2] (virus like particle) vaccine - Drug Profile 88
    influenza vaccine - Drug Profile 89
    INO-3510 - Drug Profile 91
    JNJ-3872 - Drug Profile 93
    KD-295 - Drug Profile 96
    KIN-1148 - Drug Profile 98
    Lalistat - Drug Profile 100
    M-001 - Drug Profile 101
    MBX-2329 - Drug Profile 107
    MBX-2546 - Drug Profile 108
    Monoclonal Antibodies to Inhibit Hemagglutinin for Avian Infection and Swine Flu Infection - Drug Profile 109
    Monoclonal Antibodies to Inhibit Hemagglutinin for Influenza Infections - Drug Profile 110
    MV-4 - Drug Profile 111
    Nasovax - Drug Profile 112
    NVINF-1 - Drug Profile 114
    NVINF-2 - Drug Profile 119
    OrniFlu - Drug Profile 122
    PD-001 - Drug Profile 123
    Peptides for Influenza Infections - Drug Profile 124
    PNSIA-28 - Drug Profile 125
    PNSIA-49 - Drug Profile 126
    PXVX-0103 - Drug Profile 127
    rintatolimod - Drug Profile 129
    S-033188 - Drug Profile 139
    Small Molecules for Influenza A Virus H1N1 and H5N1 Infections - Drug Profile 141
    Small Molecules to Activate Sirtuin for Influenza - Drug Profile 142
    Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile 143
    Synthetic Peptides for Viral Infections - Drug Profile 144
    TVX-003 - Drug Profile 145
    VAX-161C - Drug Profile 146
    VGX-3400X - Drug Profile 147
    VH-244 - Drug Profile 149
    VIS-410 - Drug Profile 150
    Influenza A Virus, H5N1 Subtype Infections - Dormant Projects 153
    Influenza A Virus, H5N1 Subtype Infections - Discontinued Products 156
    Influenza A Virus, H5N1 Subtype Infections - Product Development Milestones 157
    Featured News & Press Releases 157
    Appendix 167
    Methodology 167
    Coverage 167
    Secondary Research 167
    Primary Research 167
    Expert Panel Validation 167
    Contact Us 167
    Disclaimer 168

    List of Tables

    Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by Akshaya Bio Inc, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by Altimmune Inc, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by Antigen Express Inc, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by Aphios Corp, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by BioDiem Ltd, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by BiondVax Pharmaceuticals Ltd, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by CEL-SCI Corp, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by Cocrystal Pharma Inc, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by Curevac AG, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by Fab'entech SA, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by Gemmus Pharma Inc, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by GlaxoSmithKline Plc, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by Hemispherx Biopharma Inc, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by iBio Inc, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by Johnson & Johnson, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by Kineta Inc, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by Lakewood-Amedex Inc, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by Medicago Inc, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by Medigen Vaccine Biologics Corp, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by Microbiotix Inc, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by NanoBio Corp, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by Nanotherapeutics Inc, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by NanoViricides Inc, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by NewLink Genetics Corp, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by OPKO Health Inc, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by PaxVax Inc, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by PeptiDream Inc, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by Shionogi & Co Ltd, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by TechnoVax Inc, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by TGV-Inhalonix Inc, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by Vaxart Inc, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by Vaxine Pty Ltd, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by VaxInnate Corp, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Pipeline by Visterra Inc, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, H1 2017 (Contd..1) , H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, H1 2017 (Contd..2) , H1 2017
    Influenza A Virus, H5N1 Subtype Infections - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    Akshaya Bio Inc
    Altimmune Inc
    Antigen Express Inc
    Aphios Corp
    BioDiem Ltd
    BiondVax Pharmaceuticals Ltd
    CEL-SCI Corp
    Cocrystal Pharma Inc
    Curevac AG
    Fab'entech SA
    Gemmus Pharma Inc
    GlaxoSmithKline Plc
    Hemispherx Biopharma Inc
    iBio Inc
    Inovio Pharmaceuticals Inc
    Johnson & Johnson
    Kineta Inc
    Lakewood-Amedex Inc
    Medicago Inc
    Medigen Vaccine Biologics Corp
    Microbiotix Inc
    NanoBio Corp
    Nanotherapeutics Inc
    NanoViricides Inc
    NewLink Genetics Corp
    OPKO Health Inc
    PaxVax Inc
    PeptiDream Inc
    Shionogi & Co Ltd
    Takeda Pharmaceutical Company Ltd
    TechnoVax Inc
    TGV-Inhalonix Inc
    Vaxart Inc
    Vaxine Pty Ltd
    VaxInnate Corp
    Visterra Inc

    Request for Sample

    Report Url http://www.reportsweb.com//influenza-a-virus-h5n1-subtype-infections-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//influenza-a-virus-h5n1-subtype-infections-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//influenza-a-virus-h5n1-subtype-infections-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments